Two Beagles Were Gene-Edited to Reduce a Major Dog Allergen. Here Is What It Took.

Bailey and Alfie look like two perfectly ordinary young beagles: floppy ears, curious noses and plenty of enthusiasm for food. What makes them unusual is something you cannot see.

Scientists altered their DNA so their bodies would not produce detectable levels of Can f 1, one of the proteins behind many human dog allergies. In early testing, material collected from the two dogs did not trigger a skin reaction in Matt Walker, the geneticist whose company created them.

Walker knows dog allergies well. Being around dogs could leave him sneezing, rubbing itchy eyes and dealing with painful skin reactions. Even the goldendoodle his family chose partly for its hypoallergenic reputation still caused symptoms.

The possibility behind Bailey and Alfie is easy to understand: if a major allergen can be safely removed, some people who have struggled to live with dogs could eventually have another option. But creating these two puppies involved gene editing, cloning, donor dogs, a surrogate and 25 reconstructed embryos.

Understanding the story means looking at both the result and what it took to get there.

People are not usually allergic to dog fur itself. The reaction comes from proteins dogs produce and spread through saliva, dander and their coats. One of the most common is Can f 1.

Even breeds marketed as hypoallergenic can produce it, which is why choosing a poodle, doodle or another low-shedding dog does not guarantee an allergy-free home.

Walker’s team at Kindred Companion Sciences took a different approach. Instead of treating the person, they tried to remove one allergen from the dog. Using CRISPR, researchers switched off the gene responsible for Can f 1 before Bailey and Alfie were created.

When the two beagles were later tested, researchers found no detectable Can f 1 in their saliva, hair or dander. The protein was still present in samples from another beagle, a poodle and a goldendoodle.

In Bailey and Alfie, the change appears to have removed Can f 1 as intended.

Getting to that result was more complicated. Researchers used eggs from donor beagles to create 25 reconstructed embryos, which were transferred to a surrogate dog. Two developed into puppies: Bailey and Alfie, born in September 2024.

The study says the work took place at a USDA-licensed facility with veterinary and animal-care oversight. So far, both beagles have shown normal growth and activity, with no obvious health or behavioral problems reported.

Still, they are young, and scientists do not yet fully understand what Can f 1 does inside a dog’s body. That means long-term monitoring will be important before anyone can say whether removing the protein has consequences that only appear later.

Researchers also tested whether material collected from Bailey and Alfie would cause an allergic reaction. The participant reacted to samples from other dogs but showed no visible skin reaction to samples from the two gene-edited beagles.

There was one major limitation: the study included only one person, and that person was Walker himself.

Walker’s allergy testing showed that Can f 1 was the main protein behind his reactions. He has also lived with Bailey for more than a year without the allergic symptoms other dogs previously caused him.

That is encouraging, but it is still a very narrow result. Someone who reacts mainly to a different dog allergen could still have symptoms around Bailey or Alfie, so the study does not show that they are universally allergy-free.

For people with serious dog allergies, the appeal is obvious. Living with a dog can be uncomfortable or impossible, and allergies may even complicate access to working or service dogs.

If future studies show that specific allergens can be removed safely, dogs like Bailey and Alfie could offer another option. The approach might also prove more useful than relying on labels like “hypoallergenic,” which cannot guarantee that someone will avoid a reaction.

But there is still a long way to go. Researchers would need to test more people with different allergy profiles, study more dogs and follow the animals for years before knowing how safe or useful the approach really is.

The other side of the story is what that process asks us to consider.

Some people may see the process as reasonable if it eventually allows people with severe allergies to live with dogs. Others may question whether changing the animal should become part of the solution when human allergies can also be managed in other ways.

The questions become broader if the technology advances. Reducing an allergen for health reasons is very different from changing a dog’s appearance, size or behavior because people prefer a certain trait. Yet both would rely on the ability to make inherited changes in companion animals.

There is commercial context to consider as well. Walker led the study, was the only person included in the allergy test and is a founder of the company developing the technology. The research was funded by the company, two authors disclosed financial or ownership interests, and a related patent application has been filed.

That does not make the findings invalid. It does mean independent research will matter before much bigger conclusions are drawn.

Bailey and Alfie show that researchers can remove detectable levels of one major dog allergen, at least in these two dogs. What they cannot tell us yet is what happens over an entire lifetime, how people with different allergies would respond or how widely this approach should ultimately be used.

For some, the possibility will be exciting. For others, the process will raise difficult questions.

What comes next is still up for debate.